Gonorrhea - Pipeline Review, H2 2019

Published by Global Markets Direct on 11th November 2019 | Ref: 1463991 | This Product Is In Stock

$2000 | Single User
$4000 | Site License
$6000 | Enterprise License
$2000 | Single User
$4000 | Site License
$6000 | Enterprise License

Introduction

Gonorrhea - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H2 2019, provides an overview of the Gonorrhea (Infectious Disease) pipeline landscape.

Gonorrhea is a sexually transmitted disease (STD) caused by Neisseria gonorrhoeae bacterium. It can infect both males and females. The bacteria target the cells of the mucous membranes including surfaces of the urethra, vagina, cervix and endometrium, lining of the eyelid, the throat and fallopian tubes. Symptoms include painful urination, pus-like discharge from penis, increased vaginal discharge, abdominal pain and pelvic pain. Treatment includes antibiotics.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Gonorrhea - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Gonorrhea (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Gonorrhea (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Gonorrhea and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Preclinical, Discovery and Unknown stages are 4, 9, 4 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 3 molecules, respectively.

Gonorrhea (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Gonorrhea (Infectious Disease).

- The pipeline guide reviews pipeline therapeutics for Gonorrhea (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Gonorrhea (Infectious Disease) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Gonorrhea (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Gonorrhea (Infectious Disease)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Gonorrhea (Infectious Disease).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Gonorrhea (Infectious Disease) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Gonorrhea - Overview

Gonorrhea - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Gonorrhea - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Gonorrhea - Companies Involved in Therapeutics Development

Biolytics Pharma

Debiopharm International SA

Entasis Therapeutics Inc

Evofem Biosciences Inc

GlaxoSmithKline Plc

Hsiri Therapeutics LLC

Melinta Therapeutics Inc

Merck & Co Inc

Microbiotix Inc

Paratek Pharmaceuticals Inc

Pharmiva AB

Redx Pharma Plc

Gonorrhea - Drug Profiles

Amphora - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCP-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Biologic for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Debio-1453 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

edodekin alfa SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Fusion Protein for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gepotidacin mesylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gonorrhea vaccine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KKL-35 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MBX-4132 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NGoXIM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

omadacycline tosylate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PEG-2S - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PPCM - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXP-2382 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule for Bacterial Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit 16S rRNA for Gonorrhea and Chlamydia Infections - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit DNA Gyrase and Topoisomerase IV for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit PBP2 for Gonorrhea - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Tubulin for Gonorrhea and Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

solithromycin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

zoliflodacin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Gonorrhea - Dormant Projects

Gonorrhea - Discontinued Products

Gonorrhea - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Additional Details

Publisher

Global Markets Direct

Publisher Information

Reference

1463991 | GMDHC11439IDB

Number of Pages

108

Report Format

PDF

Related Reports

Title
Date Published
Price From
Link

Published by Global Markets Direct
18-03-2019

$2,000 USD

Published by Global Markets Direct
14-08-2018

$2,000 USD

Published by Global Markets Direct
20-02-2018

$2,000 USD

Published by Global Data
30-08-2017

$2,500 USD

Published by Global Markets Direct
08-08-2017

$2,000 USD

Published by Global Markets Direct
15-03-2017

$2,000 USD

This report is published by Global Markets Direct

Global Markets Direct is a global market intelligence services company providing information research and analysis products and services.

Their highly qualified team of Researchers, Analysts and Solution Consultants use proprietary data sources and various tools and techniques to gather, analyse and represent the latest and the most reliable information essential for businesses to sustain a competitive edge.

Download Free Report Summary PDF

Gonorrhea - Pipeline Review, H2 2019 | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.